Medlab Clinical Limited, a medical research and development facility, engages in the nutraceutical products and pharmaceutical research businesses in Australia. More Details
+ 1 more risk
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Medlab Clinical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MDC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MDC's weekly volatility (10%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -10.9% over the past year.
Return vs Market: MDC underperformed the Australian Market which returned 35.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Medlab Clinical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWhat We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
4 months ago | Simply Wall StMedlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
5 months ago | Simply Wall StMedlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Is Medlab Clinical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MDC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MDC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MDC is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: MDC is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MDC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MDC is overvalued based on its PB Ratio (5.8x) compared to the AU Biotechs industry average (4.9x).
How is Medlab Clinical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if MDC's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if MDC's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if MDC's revenue is forecast to grow faster than the Australian market.
High Growth Revenue: Insufficient data to determine if MDC's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDC is forecast to be unprofitable in 3 years.
How has Medlab Clinical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MDC is currently unprofitable.
Growing Profit Margin: MDC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 35% per year.
Accelerating Growth: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.6%).
Return on Equity
High ROE: MDC has a negative Return on Equity (-145.67%), as it is currently unprofitable.
How is Medlab Clinical's financial position?
Financial Position Analysis
Short Term Liabilities: MDC's short term assets (A$10.7M) exceed its short term liabilities (A$3.8M).
Long Term Liabilities: MDC's short term assets (A$10.7M) exceed its long term liabilities (A$1.8M).
Debt to Equity History and Analysis
Debt Level: MDC's debt to equity ratio (2.5%) is considered satisfactory.
Reducing Debt: MDC's debt to equity ratio has reduced from 58% to 2.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MDC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MDC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.3% each year
What is Medlab Clinical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MDC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MDC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MDC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MDC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MDC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Sean Michael Hall serves as a Chief Executive Officer and served as a Managing Director of Medlab Clinical Limited until November 2020. Dr. Hall started Medlab in August 2012. Dr. Hall has over 20 year...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD293.45K) is about average for companies of similar size in the Australian market ($USD289.57K).
Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.
Experienced Management: MDC's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.
Experienced Board: MDC's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.7%.
Medlab Clinical Limited's company bio, employee growth, exchange listings and data sources
- Name: Medlab Clinical Limited
- Ticker: MDC
- Exchange: ASX
- Founded: 2012
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$59.881m
- Shares outstanding: 342.18m
- Website: https://www.medlab.co
Number of Employees
- Medlab Clinical Limited
- 66 McCauley Street
- New South Wales
Medlab Clinical Limited, a medical research and development facility, engages in the nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for ch...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/13 08:06|
|End of Day Share Price||2021/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.